Compare BSAC & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSAC | ELAN |
|---|---|---|
| Founded | 1977 | 1954 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 12.7B |
| IPO Year | 2002 | 2018 |
| Metric | BSAC | ELAN |
|---|---|---|
| Price | $32.13 | $22.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $33.00 | $27.89 |
| AVG Volume (30 Days) | 399.1K | ★ 3.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,715,000,000.00 |
| Revenue This Year | $37.15 | $8.21 |
| Revenue Next Year | $7.52 | $5.31 |
| P/E Ratio | $14.40 | ★ N/A |
| Revenue Growth | N/A | ★ 6.22 |
| 52 Week Low | $22.77 | $9.42 |
| 52 Week High | $37.72 | $27.72 |
| Indicator | BSAC | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 43.47 |
| Support Level | $31.78 | $22.17 |
| Resistance Level | $33.36 | $22.89 |
| Average True Range (ATR) | 0.84 | 0.76 |
| MACD | -0.37 | -0.08 |
| Stochastic Oscillator | 18.40 | 26.74 |
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.